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Abstract
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide.
The main risk factors for cancers of the oral cavity, larynx, oropharynx, and hypopharynx are alcohol and
tobacco use. In addition, the human papillomavirus (HPV) is an established cause of oropharyngeal cancer.
An experienced multidisciplinary team is necessary for adequate management and optimal outcome. The
treatment of locally advanced disease generally requires various combinations of radiotherapy, surgery,
and systemic therapy, but despite this aggressive multimodal treatment, 40% to 60% of the patients will
relapse. In this report, we will discuss recent advances in the management of SCCHN, including new
developments in molecular biology, imaging, and treatment.
Introduction
SCCHN is the sixth most common cancer worldwide;
approximately 600,000 new cases are diagnosed per year
worldwide [1]. SCCHN generally begins in the mucosal
surfaces of the head and neck. The most frequent tumor
sites of SCCHN are the larynx, the pharynx, and the oral
cavity. Head and neck cancers also include salivary gland
tumors as well as nasopharyngeal cancer and paranasal
and nasal sinus cancer. These tumors are less frequent
and will not be discussed in this report.
Consumption of alcohol or tobacco is the main risk factor
for cancers of the oral cavity, larynx, oropharynx, and
hypopharynx and accounts for 75% of SCCHN. The
oncogenicHPV infection,mainlyHPV-16, is an established
cause of oropharyngeal cancer (predominantly tonsils and
base of tongue) [2,3]. Globally, the incidence of HPV-
induced oropharyngeal cancer increases each year, but
varies from less than 10% to 70% of all oropharyngeal
cancers, depending on the geographic area, being more
frequent in industrialized countries [4-6]. The etiologic role
of HPV in SCCHN sites other than oropharynx is unclear.
The treatment choice depends on the location of the
primary tumor, the stage of the disease, and the expected
oncological and functional outcomes. American Joint
Committee on Cancer (AJCC) early-stage (I/II) SCCHN is
usually treated with single-modality therapy (i.e. surgery
or radiotherapy [RT]). The management of locally
advanced disease (AJCC stage III/IV) generally requires
various combinations of RT, surgery, and chemotherapy
or cetuximab. The survival rates for all patients with
SCCHN are approximately 40% to 60% at 5 years [7]. In
this report, we review recent advances in the management
of SCCHN, including new developments in molecular
biology, imaging, and treatment.
1. Clinical relevance of SCCHN molecular
biology
The epidermal growth factor receptor (EGFR) is a
transmembrane tyrosine kinase receptor belonging to
the HER/erbB family and is overexpressed in up to
90% of SCCHN [8]. High EGFR gene copy number has
been reported in 10% to 58% of SCCHN [9-12]. In
SCCHN, in contrast to lung cancer, activating EGFR
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mutations are rare. Overexpression of EGFR and high
EGFR gene copy number are associated with poor
prognosis and radioresistance [9-17]. The EGFR is a
relevant target in SCCHN since cetuximab, an immu-
noglobulin G1 (IgG1) monoclonal antibody targeting
the EGFR, improves overall survival (OS) when
combined with RT or chemotherapy [18,19]. However,
only a minority of patients will benefit from anti-
EGFR monoclonal antibodies, and the objective
response rate in monotherapy is between 6% and
13% [20,21].
Recently, deep sequencing technology has allowed a
better characterization of the implicated genes [22-24].
Somatic mutations in TP53 (47% to 72%), NOTCH1
(14% to 19%), CDKN2A (9% to 22%), PIK3CA (6% to
21%), FBXW7 (5%), HRAS (4% to 8%), FAT1 (23%),
and CASP8 (8%) have been reported. Besides these
mutations, some genes or their related proteins have
been found to be altered by other mechanisms
(amplification, deletion, epigenetic) [25-29]. Altogether,
activating mutations in classic oncogenes seem relatively
rare in SCCHN and most of the genetic alterations occur
in tumor suppressor genes. These findings are important
for the further development of novel therapies for
SCCHN, although developing new compounds to restore
the activity of altered tumor suppressor genes like p53 or
CDKN2A is extremely challenging.
Most of the genetic alterations described above have
been found in HPV− tumors. Biologically, HPV-induced
SCCHN is different and is characterized by the
inactivation of the p53 tumor suppressor gene by the
viral oncoprotein E6 and the retinoblastoma suppressor
gene by the HPV oncoprotein E7 [30,31] (Figure 1).
Globally, HPV+ tumors have fewer genetic alterations
than HPV− tumors [24,32]. Interestingly, activation of
the phosphoinositide 3-kinase (PI3K) pathway appears
quite frequent in HPV+ tumors [33]. Many studies have
shown that patients with HPV+, p16+, or p53 wild-type
tumors have better OS and progression-free survival
(PFS) rates than patients with HPV−, p16−, or p53
altered SCCHN [34-36]. Ang and colleagues classified
patients with SCCHN as having a low, intermediate, or
high risk of death on the basis on four factors: HPV
status, pack-years of tobacco smoking, tumor stage, and
nodal stage [2]. Therefore, it is crucial that future
clinical trials select or at least stratify patients according
to their HPV and risk status. Since the prognosis
for patients with HPV+ is better, specific trials investi-
gating treatment de-intensification in this population
are ongoing. However, today without the results of
these trials, HPV+ tumors must be treated with the same
regimens as HPV− tumors.
2. Challenges and perspectives in imaging
work-up
2.1. Positron emission tomography
Positron emission tomography (PET) is a non-invasive
procedure using tracers labeled with positron emitters
such as fluorine-18. The most frequently used tracer in
clinical practice is 18F-fluorodeoxyglucose (FDG), an
analog of glucose, allowing metabolic mapping of the
entire body in one procedure. In the last decade, all
manufacturers have developed PET cameras coupled with
conventional computerized tomography (CT) scanners
(PET-CT), allowing instant fusion of anatomical and
metabolic images, leading to better anatomic localization
of lesions and increasing accuracy [37].
In head and neck cancers, some controversies have arisen
about some specific indications [38]. There is a large
consensus for the role of PET in the detection of occult
primary SCCHN, staging and restaging of patients with
high-risk of disseminated disease, and the assessment of
lesions of unknown origin [39-41].
In addition, PET has an increasing role in therapy response
assessment after chemoradiotherapy (CRT) in SCCHN,
showing a high negative predictive value in neck evalua-
tion when performed 12-weeks after completion of
treatment [42-44]. This post-therapy evaluation to identify
which patient will benefit from neck dissection is
Figure 1. Molecular biology of human papillomavirus (HPV)-
positive squamous cell carcinoma of the head and neck (SCCHN)
HPV-induced SCCHN is characterized by the inactivation of the p53 tumor
suppressor gene by the viral oncoprotein E6 and the retinoblastoma (Rb)
suppressor gene by the HPV oncoprotein E7. Inactivation of the Rb gene
induces the release of the E2F transcriptional factor that leads to cell cycle
progression (G1 to S phase). Inactivation of p53 removes the break of p21
on cyclin-dependent kinase (CDK) activity. All together, these molecular
alterations lead to cell cycle progression and cell division.
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considered an indication by National Comprehensive
Cancer Network and Society of Nuclear Medicine guide-
lines [40,41]. However, some data suggested no added
value of PET compared with conventional imaging in this
purpose, but these data were acquired on a PET-alone
camera (not PET-CT) and performed as early as 7-weeks
after completionof treatment [45]. Residual inflammation
is known to increase the rate of false-positive uptake in
these delays. Ongoing studies such as PET-NECK and
GETTEC (Groupe d’Etude des Tumeurs de la Tete et du
Cou) studies should further clarify the precise role of
PET-CT in this indication.
Intense research is ongoing in radiation oncology to
evaluate the role of molecular imaging for target
volume delineation. In particular, FDG (glucose
uptake) or other tracers such as [18F]-fluorothymidine
(FLT, proliferation tracer) and [18F]-fluoroazomycin-
arabinoside (FAZA, hypoxia tracer) are currently studied
for their potential ability to identify subzones of the
tumor with more hypoxia (FAZA) or tumor proliferation
(FLT) [46,47]. This information could lead radiation
oncologists to target small areas of the tumor with higher
radiation doses (‘dose painting’) to reach better local
control [48].
2.2. Computed tomography and magnetic resonance
Tumor imaging
Both CT scanner and magnetic resonance imaging (MRI)
are giving highly relevant information about location, size,
shape, and contours of the primary tumor [49]. The two
modalities have specific advantages but also suffer from
significant limitations: ‘fast’ CT is able to freeze motion
artefacts and has the unsurpassed advantage in yielding
information about electron density, useful for RT plan-
ning. ‘Slow’ MRI has the major advantage of enhancing
soft tissue contrast, including the bone marrow, whereas
CT detects the mineralized tissues. Main limitations of
both modalities are the overestimation of the gross tumor
volume by 30% to 60% when compared with FDG-PET
because of their inability to separate the tumor from the
adjacent reactive changes [50].
Nodal imaging
Morphological CT or MRI images have insufficient
diagnostic accuracy because nodal size is not a robust
predictor of the presence of metastases. CT and MRI
perform similarly in nodal staging. Enlarged nodes can be
benign (inflammatory changes), and small-sized nodes
can host micro-metastases. When a cutoff value at 10 mm
(short axis diameter) is used, an overall diagnostic
accuracy of only 80% is achieved by both modalities
[51]. Twenty-five percent of clinically and radiologically
N0 necks are positive at histopathology. Other criteria
such as heterogeneity (central necrosis), round shape,
differential enhancement, irregular margins (suggesting
extra-nodal spreading), and clustering of more than three
nodes are being considered as ancillary criteria for
malignancy but require validation [52].
Distant metastases imaging
Newly available multi-row CT systems are used for
metastatic work-up. Emerging ‘whole-body’ MRI techni-
ques combining morphological imaging and diffusion-
weighted imaging (DWI) hold major promise in the
field [53].
2.3. Diffusion- and perfusion-weighted imaging
DWI gives a quantitative index of the free-water diffusion
restriction as encountered in tissues with high cellular
density. For tumor imaging, the DWI technique allows
tumor characterization at initial work-up (benign versus
malignant), pre-treatment prognosis, early treatment
response evaluation, and recurrence detection [54]. For
nodal imaging, DWI seems extremely useful to differenti-
ate tumoral and non-tumoral nodes but with the limita-
tion that the DWI technique is uneasy to standardize and
requires expertise in pulse sequence programming, image
processing, and quantitative data interpretation [55].
Perfusion-weighted imaging (PWI) has shown the
ability to predict patient outcome [56]. Multiparametric
approaches combining PET metabolic information and
MRI ‘functional’ DWI or PWI data (or both) are currently
being investigated [57,58].
3. Challenges and perspectives in (chemo)
radiation
The head and neck region contains numerous intricately
organized organs essential for basic physiological func-
tions and critical for physical appearance, expression,
and social interactions. Therefore, minimizing radiation-
related toxicities is the main challenge.
Technological innovations have greatly changed the way
the dose is delivered. The use of three-dimensional
treatment planning and the ability to modulate the
beams during treatment allowed a more accurate dose
delivery with steeper dose gradients around the target
volume, allowing a decrease of the dose to the
surrounding organs at risk while maintaining target
coverage (Figure 2) [59]. This so-called intensity-modu-
lated radiotherapy (IMRT) was rapidly implemented in
SCCHN as it allowed a significant sparing of the
contralateral parotid, effectively reducing the rate of
severe late xerostomia in these patients without com-
promising outcome [60-62]. The role of IMRT in
reducing other toxicities such as late dysphagia is
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currently being investigated [63-65]. On the other
hand, the effect of IMRT on tumor control is much
debated. As poorly implemented, it harbors an increased
risk of missing the target volume [66,67]. Internationally
endorsed delineation guidelines are of paramount
importance to reduce inter-observer and inter-patient
treatment variations and have proven essential in the
conduction of multi-institutional clinical trials [68-70].
A recent analysis of the Surveillance, Epidemiology, and
End Results (SEER) database demonstrated that the use
of IMRT was associated with a significant improvement
in cause-specific survival compared with non-IMRT
techniques [71]. There is growing interest in using
IMRT in strategies to increase tumor control by escalating
the dose to the target volume. For example, the
information provided by imaging techniques such as
FDG-PET and functional MRI could improve target
volume delineation and might even identify regions of
increased radioresistance within the tumor [50,72,73].
Therefore, we have both the rationale and the means to
target these subvolumes selectively with a higher radia-
tion dose without increasing the doses to the surround-
ing organs at risk. Theoretically, such a so-called ‘dose-
painting’ approach could increase tumor control while
maintaining the same toxicity levels. Other approaches
have already been investigated. In an attempt to exploit
the differential sensitivity between tumor cells and
normal tissue, the idea arose to deviate from conven-
tional fractionation schedules [74]. In a large meta-
analysis, Bourhis et al. found that altered fractionation
schedules improve survival compared with conventional
fractionation [75].
The combination of RT with chemotherapy and other
radiosensitizers has been investigated. The updatedmeta-
analysis of chemotherapy in combination with radiation
for SCCHN (Meta-Analyses of Chemotherapy in Head
and Neck Cancer, or MACH-NC) showed that the
addition of chemotherapy concomitantly to radiation
improves the absolute 5-year survival by 6.5% [76,77].
Concomitant platinum-based CRT is the standard of care
in locally advanced SCCHN.
The exact role of induction chemotherapy with
docetaxel, cisplatin, and 5-fluorouracil (TPF) remains
controversial and investigational. So far, several rando-
mized trials testing sequential approaches with TPF
induction followed by concurrent CRT versus concurrent
CRT alone have been reported [78-80]. They failed to
demonstrate a statistically significant difference in OS and
PFS. Cetuximab combined with RT improves locoregional
control and OS rate compared with RT alone, apparently
without increasing the radiation-induced side effects [81].
Cetuximab-RT is therefore considered an alternative to
CRT; however, so far there are no data comparing CRT
with cetuximab-RT.
In an attempt to improve outcome, several studies have
attempted to combine the above-mentioned treatment
strategies. In both the RTOG (Radiation Therapy Oncol-
ogy Group) 0129 and the GORTEC (Groupe Oncologie
Radiothérapie Tête et Cou) 99-02 trials, accelerated CRT
failed to demonstrate a benefit compared with conven-
tionally fractionated CRT [2,82]. Both trials concluded
that acceleration seemed unable to compensate for the
absence of concurrent chemotherapy. Similarly, the
combination of EGFR targeting drugs with CRT has
failed to demonstrate any benefit so far [83,84].
4. Challenges and perspectives in surgery
In the past, advanced resectable tumors were preferentially
treated by primary radical surgery followed by adjuvant
RT. During the nineties, the development of CRT
dramatically changed the role of surgery for locally
advanced SCCHN, in particular when a voice-sparing
surgical approach was not possible [85-87]. Today,
primary total pharyngolaryngectomy remains indicated
only in very advanced resectable cancer, when the ability
to recover a functional organ after CRT is low. Open
surgery remains the best primary treatment for a majority
of head and neck tumors localized in the oral cavity,
salivary glands, thyroid gland, nose and paranasal sinus,
skull base, and skin as well as for sarcomas of the head
and neck [88].
The concept of minimally invasive surgery includes laser
and robotic surgery. For small transorally accessible
Figure 2. The potential of intensity-modulated radiotherapy
(IMRT)
A squamous cell carcinoma of the left tonsil from a 58-year-old patient was
classified as cT4aN2c. IMRT allows steep dose gradients to be generated,
ensuring an adequate target coverage while sparing surrounding at-risk
organs such as the contralateral parotid gland (dark green) and the spinal
cord (light green).
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cancers of the oral cavity, pharynx, and larynx, surgical
excision can be achieved with functional preservation of
the involved organ and good oncological results. Trans-
oral laser surgery is less invasive compared with many
open procedures. However, oncologic and functional
outcomes of early glottic cancers do not seem better with
laser surgery than with radiation, despite the lack of
prospective randomized trials [89,90]. For locally
advanced laryngeal cancer, good long-term oncological
outcome with laser microsurgery was recently reported
[91,92]. Regarding oropharynx, minimally invasive
approaches, including transoral laser microsurgery and
recently robotic surgery, have shown improved functional
outcomes and oncologic outcomes similar to primary
radiation [93]. There is little doubt that transoral robotic
surgery, in experienced hands, is associated with less
morbidity than traditional open surgery. Resection is
possible without a mandibulotomy approach. However,
we should be prudent about assuming that something
must be better just because it is newer: in one series,
suboptimal exposure was reported in 26% and post-
operative hemorrhages in 12%, leading to death in 2%
[94]. Currently indicated for early oropharyngeal carci-
noma, this approach has been employed in the manage-
ment of supraglottic cancer. However, with the exception
of base of tongue tumors, many T1-T2 oropharynx cancers
can be resected transorally. Importantly, regardless of the
surgical approach, elective neck dissection is recom-
mended in patients clinically N0 because the risk of
occult lymph node metastases is around 30% [95].
Typically, unilateral or bilateral dissection of levels II, III,
and IV is indicated in oropharynx cancer. Robust data
from a randomized trial comparing oncologic and
functional outcomes of transoral surgery plus elective
neck dissection versus RT including the tumor site and
the lymph nodes at risk in the clinical target volume are
lacking.
Regarding advanced head and neck squamous cell
carcinoma, the emergence of organ preservation strate-
gies has considerably limited the role of primary surgery
in this setting. The surgeon is more frequently faced with
failures of primary non-surgical therapies. Besides the
expertise of the surgeon, an accurate selection of the
patients who are suitable for surgery and who require a
combination of large resection and well-vascularized flap
reconstruction is key in salvage surgery. Although the
definition of unresectability is not uniform, it is typically
accepted that a tumor invading the common carotid
artery, the base of the skull, or the prevertebral muscles
should be considered unresectable. Advances in micro-
revascularized free flaps have considerably expanded the
possibilities of reconstruction following resection of
advanced tumors. Accurate tailoring of the flap improves
the cosmetic result and the functional outcome (Figure 3).
Use of these flaps has allowed voice-preservation surgery
for selected patients with advanced hypopharyngeal or
laryngeal cancer, even after failure of organ-sparing
therapy [96].
When surgery is the primary treatment, neck dissection is
recommended in most tumors with the exception of
early tumors of the vocal cord. The rationale for a
selective neck dissection is based on known patterns of
metastases from each site. Currently, selective neck
dissection is an oncologically safe and low-morbidity
surgical procedure indicated for clinically negative necks
harboring a risk of micrometastasis in up to 30% and for
clinically N1 disease [97,98]. In patients treated with
primary CRT, neck dissection is recommended when
residual disease is suspected, whereas its role remains
controversial in the setting of complete response
[99,100]. However, because patients achieving a com-
plete clinical response to CRT have a very low risk of an
isolated neck recurrence, the strategy of systematic neck
dissection is no longer justified [101]. The next issues are
to identify patients who have residual anatomic abnorm-
alities with no viable tumor cells and to improve the
outcome of patients who have pathological residual
disease. Use of less morbid neck dissection after CRT was
progressively proposed in patients initially staged N2-N3
with a very low rate of subsequent neck failure [102,103].
Figure 3. Oropharyngectomy through mandibular swing
approach
Reconstruction of the soft palate and lateral oropharynx with a
microrevascularized radial forearm free flap (arrows) is shown.
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Many publications support the suitability of selective
neck dissection after chemoradiation in patients with
initially advanced regional disease and in patients with
clinically persistent disease [98,104-106].
5. Recurrent or metastatic disease or both
SCCHN that recurs after multimodal local treatment is
generally considered incurable if the patient cannot be
salvaged by surgery or additional RT. Platinum-based
chemotherapy in combination with cetuximab is consid-
ered the standard of care in fit patients. The combination
of cisplatin or carboplatin with 5-fluorouracil and
cetuximab improvesOS (medianOS is 10.1months) [18].
Docetaxel, paclitaxel, and methotrexate are other che-
motherapy compounds sometimes used in this indication.
Based on the improvement in SCCHN molecular biology
knowledge, new compounds are currently being investi-
gated (EGFR/HER-3 dual, irreversible pan-HER or PI3K
inhibitors, cell cycle inhibitors) [107].
Conclusions
SCCHN is a heterogeneous disease at both the
anatomical and molecular levels. An experienced
multidisciplinary team is necessary for adequate man-
agement and to optimize the outcome. Despite multi-
modal treatment, including surgery, RT, chemotherapy,
or some combination thereof, 40% to 60% of the
patients with locally advanced SCCHN will relapse.
Further treatment intensification with these classic
treatment modalities is almost impossible since the
maximal tolerable toxicity is reached, limiting further
improvement in treatment.
Improvement in technology, including imaging, radiation
technique, and surgery, has allowed better functional and
cancer outcomes. Ongoing trials address important
questions regarding treatment sequences (i.e., induction
versus concomitant CRT, de-escalation in HPV+ cancer,
induction followed by cetuximab-RT). In addition, our
better understanding of the molecular biology of the
disease has opened new treatment avenues that should be
explored in the near future with the hope that targeted
therapies may help to circumvent the toxicities of the
classic modalities. However, only a minority of patients
seem to benefit from molecular targeted therapies.
Therefore, a major challenge in coming years will be to
identify predictive biomarkers to tailor each treatment to
the most appropriate population.
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